Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Mindbio Therapeutics Corp. ( (TSE:MBIO) ).
MindBio Therapeutics Corp. announced the results of its Phase 2B clinical trial investigating the effects of microdosed LSD on Major Depressive Disorder (MDD). The trial found that microdosed LSD did not significantly reduce depression severity compared to placebo, although it showed mood-elevating effects and sleep improvements in healthy individuals. Despite the trial’s primary outcome, the company continues to advance its product development and AI-driven technologies, such as the Booze AI app, which analyzes speech to predict alcohol intoxication.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a clinical-stage biotechnology company based in Vancouver, British Columbia. The company is involved in leading clinical health research and product development, focusing on mental health treatments and leveraging AI and machine learning technologies.
Average Trading Volume: 460
Technical Sentiment Signal: Sell
Current Market Cap: C$3.68M
For a thorough assessment of MBIO stock, go to TipRanks’ Stock Analysis page.